Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: Polypoidal Choroidal Neovascularization or Idiopathic Choroidal Vasculopathy

Yeungnam University College of Medicine

Status: Unknown

Conditions: Polypoidal Choroidal Vasculopathy

Treatments: Drug: Aflibercept; Drug: Indocyanine green angiography (intraveonus indocyanine green dye)

Study type: Observational

Funder types: Other

Identifiers

NCT02597855

YUMC2015-08-036

Details and patient eligibility

About

To compare the short-term effect of intravitreal aflibercept injection between two subtypes of polypoidal choroidal vasculopathy

Full description

The subjects were classified into two subtypes (type 1 and type 2 polypoidal choroidal vasculopathy) based on the presence or the absence of both of a feeder and a draining vessels on indocyanine green angiography. All received intravitreal injection of aflibercept (2.0 mg) at baseline and months 1, 2 and 4.

Enrollment: 29 patients

Sex: All

Ages: 45 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. symptomatic typical PCV accompanying branch vascular network involving subfoveal area
2. signed informed consent; and
3. over 6 months follow-up period after enrollment.

Exclusion criteria

1. retinal diseases other than PCV
2. extrafoveal PCV not involving subfoveal area
3. massive subretinal hemorrhage blocking polypoidal lesion on ICGA
4. severe media opacity such as senile cataract
5. previous history of intravitreal injection
6. previous intraocular surgery history except cataract surgery which was done more than 3 months.

Trial design

29 participants in 2 patient groups

Type 1 polypoidal choroidal vasculopathy

Description:

Monthly intravitreal aflibercept injection for 3 months and 1 additional injection after 2 months. Indocyanine green angiography was used to classify the type of PCV and evaluate the polyp closure rate.

Treatment:

Drug: Indocyanine green angiography (intraveonus indocyanine green dye)

Drug: Aflibercept

Type 2 polypoidal choroidal vasculopathy

Description:

Monthly intravitreal aflibercept injection for 3 months and 1 additional injection after 2 months. Indocyanine green angiography was used to classify the type of PCV and evaluate the polyp closure rate.

Treatment:

Drug: Indocyanine green angiography (intraveonus indocyanine green dye)

Drug: Aflibercept